The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
Official Title: A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
Study ID: NCT01911936
Brief Summary: This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.
Detailed Description: This is a phase I, open-label, dose-escalation study to establish the MTD and/or RDE of LJM716 as single agent in Japanese patients that have advanced solid tumors. The study consists of a dose escalation part and a dose expansion part.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Novartis Investigative Site, Koto, Tokyo, Japan
Novartis Investigative Site, Fukuoka, , Japan
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR